Jubilant Life Sciences Ltd has received approval for US FDA approval for the epilepsy drug levetiracetam injection. “The company has received Abbreviated New Drug Application (ANDA) final approval for levetiracetam injection 500 mg/5 mL (100 mg/mL), the generic version of Keppra injection of UCB, which is used for the treatment of epilepsy,” said Jubilant Life Sciences in a press release.
As on March 31, 2016, Jubilant Life Sciences had a total of 739 filings for formulations of which 517 have been approved in various regions globally. This includes 72 ANDAs filed in the US, of which 44 have been approved and 46 Dossier filings in Europe.
